Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Orphazyme A/S    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Orphazyme A/S : Notice to convene Annual General Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2019 | 08:01am EDT

Orphazyme A/S
Company announcement                                                                                                                  

No. 06/2019                                                                                                                                        
Company Registration No. 32266355                                                                                                                                                                    

 

Copenhagen, Denmark, March 5, 2019Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Orphazyme A/S Annual General Meeting will be held on:

Wednesday, March 27, 2019 at 5:00 PM (CET)

at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.

The notice to convene the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached.

Additional information about the Annual General Meeting is available at Orphazyme A/S’ website,
http://phx.corporate-ir.net/phoenix.zhtml?c=254662&p=irol-agm.

 

For additional information, please contact

Orphazyme A/S
Anders Vadsholt, CFO                         +45 28 98 90 55

 

About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com

Forward-looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachments

  • 06-2019 Notice to convene Annual General Meeting
  • Notice to Convene AGM 2019
  • Appendix 1

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ORPHAZYME A/S
10/02ORPHAZYME A/S : Major shareholder announcement
AQ
09/17ORPHAZYME A/S : CMO to speak at FDA-funded rare disease data analytics platform ..
AQ
08/28ORPHAZYME A/S : announces Interim Report First Half 2019
AQ
08/27ORPHAZYME A/S : strengthens balance sheet with EUR 9 million financing from Kreo..
AQ
08/21ORPHAZYME A/S : Interim Report First Half 2019 Presentation
AQ
08/05ORPHAZYME A/S : Major shareholder announcement
AQ
08/01CYTRX CORPORATION : Highlights Arimoclomol Licensee Orphazyme A/S Prepares for R..
AQ
07/29ORPHAZYME A/S : New phantom share-based incentive program
AQ
07/29ORPHAZYME A/S : New share-based incentive program
AQ
07/29ORPHAZYME A/S : New incentive program for the Board of Directors of Orphazyme
AQ
More news
Financials (DKK)
Sales 2019 -
EBIT 2019 -329 M
Net income 2019 -322 M
Finance 2019 72,3 M
Yield 2019 -
P/E ratio 2019 -3,17x
P/E ratio 2020 -5,44x
EV / Sales2019 infx
EV / Sales2020 260x
Capitalization 1 023 M
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 124,67  DKK
Last Close Price 51,20  DKK
Spread / Highest target 181%
Spread / Average Target 143%
Spread / Lowest Target 111%
EPS Revisions
Managers
NameTitle
Anders Mørkebjerg Hinsby Chief Executive Officer
Georges Gemayel Chairman
Anders Fink Vadsholt Chief Financial Officer
Thomas Kirkegaard Jensen Chief Scientific Officer
Thomas Blaettler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ORPHAZYME A/S18.11%153
GILEAD SCIENCES5.29%83 409
VERTEX PHARMACEUTICALS10.75%49 109
REGENERON PHARMACEUTICALS-19.33%32 970
WUXI APPTEC CO., LTD.60.93%19 694
GENMAB33.96%13 865